

# Genomically Guided Radiotherapy for DCIS at GenesisCare Mater

## DCISionRT®

Welcome to a New Paradigm for DCIS Management

### Predicts radiation benefit.

DCISionRT is the only test capable of predicting an individual patient's benefit from radiation therapy. Using DCISionRT provides you with 10-year Total and Invasive Recurrence Risk after breast conserving surgery as well as surgery with radiation therapy. No other test can do this.


### Enables precision medicine.

DCISionRT provides you the information to deliver precision medicine to your patients. Unlike grade, tumor size or patient age, DCISionRT quantifies a woman's risk based on her DCIS biology. Studies have shown that DCISionRT reclassifies over 50% of patients compared to grade and size [REF CCR]. The future of DCIS management is here with DCISionRT.

### Unmatched clinical evidence.

DCISionRT has undergone multiple independent validations, including the landmark SweDCIS randomized clinical trial. The test has the highest dynamic range and most consistent results study to study. Evidence includes over 2000 patients from development through validation. No other test is backed by this level of clinical evidence.

## DCISionRT® The Only Predictive DCIS Test.




Wimberg F, et al. SABCS 2017; Publication Number G55-08 – AACR; Cancer Res 2018;78(4 Suppl)Abstract nr G55-08.

DCISionRT provides physicians with the first radio-genomics tool to predict radiation therapy benefit.


In an independent clinical validation of DCISionRT in the landmark SweDCIS randomized clinical trial, patients with low Decision Scores no significant invasive risk reduction from radiation therapy after surgery whereas patients with elevated Decision Scores had a 9% reduction in invasive risk (HR 0.24, p=0.012). This study, for the first time, demonstrates a DCIS test that predicts the extent to which patients benefit from radiation therapy.

# DCISionRT enables physicians to deliver precision medicine to DCIS patients

## Traditional Clin/Path Reclassified by DCISionRT®



## 10 Year Total Recurrence Risk Traditional Clin/Path vs DCISionRT®



In a multisite study including 474 DCIS patients, DCISionRT substantially reclassified DCIS patient risk compared to traditional clinicopathologic risk assessment, such as grade (shown). In fact, 53% of patients with low or intermediate grade DCIS (grade 1 or 2) were upstaged to elevated risk by DCISionRT and 30% of patients with high grade DCIS (grade 3) were identified as low risk by DCISionRT<sup>1</sup>. With DCISionRT, patients and physicians have access to a test that enables truly personalized treatment based on a patient's individual biology.

Traditional risk assessment using DCIS grade to DCISionRT risk groups indicates the power of the DCISionScore. While traditional risk assessment with DCIS grade shows little difference for low/intermediate grade DCIS (grade 1 & 2) compared to high grade DCIS, DCISionRT distinguishes which patients have a clinically low risk (DCISionScore ≤3) from those with clinically elevated risk (DCISionScore >3). With DCISionRT, Know Your Risk™.

Results are shown are for the 196 patients treated with conserving surgery treated patients with clear margins in a multisite study. Total recurrence risks shown are adjusted for year of diagnosis. This was demonstrated in a multisite study of 474 patients<sup>1</sup>.

<sup>1</sup> Bremer T, Whitworth P, Patel R, et al. . A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk. Clin Cancer Res . 2018; doi:10.1158/1078-0432.CCR-18-0842.

## What information does DCISionRT give me?

Based on the biology of your DCIS, the DCISionRT test provides you and your physician the information needed to make a decision whether surgery alone or surgery with radiation therapy is appropriate.



### DCISionRT® Score Results

DCISionRT provides a woman's individual DCISionScore on a scale from zero to ten, which corresponds to recurrence risks.



### 10 Year Total Risk (DCIS + Invasive)

Total risk is the chance of having either a DCIS recurrence or developing invasive breast cancer within 10-years.



### 10 Year Invasive Risk (Invasive Only)

Invasive risk is the probability of developing invasive breast cancer in the breast originally diagnosed with DCIS within 10-years.